Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.

Autor: Cummings S; Myriad Genetics Inc., Salt Lake City, UT, USA., Roman SS; Myriad Genetics Inc., Salt Lake City, UT, USA., Saam J; Myriad Genetics Inc., Salt Lake City, UT, USA., Bernhisel R; Myriad Genetics Inc., Salt Lake City, UT, USA., Brown K; Myriad Genetics Inc., Salt Lake City, UT, USA., Lancaster JM; Myriad Genetics Inc., Salt Lake City, UT, USA., Usha L; The Rush Cancer Institute, Rush University, 1725 W. Harrison St. #309, Chicago, IL, 60612, USA. lydia_usha@rush.edu.
Jazyk: angličtina
Zdroj: Journal of ovarian research [J Ovarian Res] 2021 Apr 29; Vol. 14 (1), pp. 61. Date of Electronic Publication: 2021 Apr 29.
DOI: 10.1186/s13048-021-00809-w
Abstrakt: Background: Professional society guidelines recommend risk-reducing salpingo-oophorectomy (RRSO) for women with pathogenic variants (PVs) in ovarian cancer-risk genes. Personalization of that intervention is based on gene-specific phenotypes; however, the age of ovarian cancer diagnosis in women with PVs in moderate penetrance ovarian cancer-risk genes is not well characterized. Women who had hereditary cancer panel testing from September 2013-May 2019 were included (N = 631,950). Clinical/demographic information was compared for women with a PV in BRIP1, RAD51C, or RAD51D versus in BRCA1 or BRCA2.
Results: PVs in BRIP1, RAD51C, or RAD51D were identified in 0.5% of all tested women but in 1.6% of women with a history of ovarian cancer (~ 3-fold increase). PVs in BRCA1 or BRCA2 were identified in 2.4% of all tested women but in 6.1% of women with a history of ovarian cancer (~ 2.5-fold increase). The proportion of women with a personal or family history of ovarian cancer was similar among women with a PV in BRIP1, RAD51C, RAD51D, BRCA1, or BRCA2. The median age at ovarian cancer diagnosis was 53 years for BRCA1, 59 years for BRCA2, 65 years for BRIP1, 62 years for RAD51C, and 57 years for RAD51D.
Conclusions: These data reinforce the importance of identifying PVs in moderate penetrance ovarian cancer-risk genes. The age at ovarian cancer diagnosis was older for women with PVs in BRIP1, RAD51C, or RAD51D, suggesting that it is safe to delay RRSO until age 45-50 in RAD51D PV carriers and possibly until age 50-55 in BRIP and RAD51C PV carriers.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje